Good morning to you all. Please find enclosed a summary of the breaking small-cap and micro-cap financial news we highlighted on AGORACOM Small Cap TV this morning. It’s April 29th, 2011, and we’ve found 2 great press releases to report on at the open. Another great day for small-cap and micro-cap financial news. To watch the show live every morning at 9:30 AM, visit our front page.

Operating Activities was $8.9 million, up 272% from $2.4 million for 2009

-- Cash and restricted cash on hand was $8.6 million

-- Silver production totalled 2,275,817 ounces, down 6% from 2,427,156 for 2009

-- Generated gross proceeds of $6.9 million through a bought deal private placement

ABOUT U.S. SILVER CORPORATION

U.S. Silver, through its wholly owned subsidiaries, owns and/or operates the Galena, Coeur, Caladay and Dayrock silver-lead-copper mines in Shoshone County, Idaho, with the Galena mine being the second most prolific silver mine in US history. Total silver production from U.S. Silver's mining complex has exceeded 217 million ounces of silver production since 1953. U.S. Silver controls a land package now totaling approximately 14,000 acres in the heart of the Coeur d'Alene Mining District. U.S. Silver is focused on expanding the production from existing operations as well as exploring and developing its extensive SilverValley holdings in the Coeur d'Alene Mining District.

Last: 0.70Range: 0.83-0.165 Market Cap: 204.8 million

Link to hub

China Pharmaceuticals, Inc. Announces Fiscal Year 2010 Results

China Pharmaceuticals, Inc. (OTC Bulletin Board: CFMI)("China Pharmaceuticals" or the "Company"), one of China's leading manufacturers and distributors of prescription and over-the-counter pharmaceuticals today announced its financial results for fiscal year ended December 31, 2010. The Company's annual report on Form 10-K was filed with the U.S. Securities and Exchange Commission on April 15, 2011.

Fiscal Year 2010 Highlights

-- Total net sales increased to $34,184,906 from $26,708,285 in fiscal 2009, an increase of $7,476,621 or approximately 28%.

-- Gross profit increased to $19,436,665 from $14,300,250 in fiscal 2009, an increase of approximately 36%. Gross profit margin improved to 57% versus 54% for 2009.

-- Cost of goods sold, as a percentage of sales, decreased to 43% in fiscal 2010, as compared to 46% in 2009.

-- Net income was $8,409,158 compared to $8,907,379 in fiscal 2009, a decrease of approximately 5% which was primarily due to a one time stock-based compensation expense of $2,222,622 for issuance of warrants during the period.

-- Net working capital increased to $20,556,811 at December 31, 2010, an increase of $11,313,690, or approximately 82 %, as compared to net working capital of $9,243,121 at December 31, 2009.

About China Pharmaceuticals, Inc.

China Pharmaceuticals, Inc. has its headquarters in the industrial city of Xi'an, Shaanxi Province, China. The Company identifies, discovers, develops, manufactures and distributes both prescription and over-the counter, including both conventional and traditional Chinese Medicines, pharmaceutical products for the treatment of some of the most common ailments and diseases. The Company currently manufactures 85 pharmaceutical products in the form of capsules, oral solutions, tablets, granules, syrups, medicinal teas, tincture and solutions for injection.

Last Trade: 4.2552 Week: 6.00 – 2.10Market Cap: 48.45 Million